Overview

A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate change of over active bladder symptom scores (OABSS) between, before and after solifenacin treatment to OAB subjects.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma Korea, Inc.
Treatments:
Solifenacin Succinate